BioRestorative Therapies (BRTX) Notes Payables (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Notes Payables came in at $1.4 million in Q4 2025, down 44.49% YoY from $2.5 million in Q4 2024, and down 28.91% on a QoQ basis from $2.0 million in Q3 2025.
BioRestorative Therapies (BRTX) Notes Payables (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 15 years of Notes Payables data on file, last reported at $1.4 million in Q4 2025.
- Quarterly Notes Payables fell 44.49% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 44.49% YoY) and the FY2025 annual result came in at $1.4 million, down 44.49% from the prior year.
- Notes Payables slipped to $1.4 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $14.2 million in Q1 2022 to a low of $1.4 million in Q4 2025.
- A 4-year average of $4.8 million and a median of $3.3 million in 2024 frame the typical range for Notes Payables.
- Annual changes were most pronounced in 2023 — Notes Payables plunged 72.14% — and 2024, when it soared 67.32%.
- Tracing BRTX's Notes Payables over 4 years: stood at $5.5 million in 2022, then sank by 72.14% to $1.5 million in 2023, then surged by 63.27% to $2.5 million in 2024, then sank by 44.49% to $1.4 million in 2025.
- The last three Notes Payables figures came in at $1.4 million (Q4 2025), $2.0 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 2.58 Mn |
| Mar 31, 2025 | 3.15 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 4.49 Mn |
| Mar 31, 2024 | 2.76 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 9.76 Mn |
| Mar 31, 2023 | 7.03 Mn |
| Dec 31, 2022 | 5.54 Mn |
| Sep 30, 2022 | 7.22 Mn |
| Jun 30, 2022 | 6.43 Mn |
| Mar 31, 2022 | 14.21 Mn |
| Mar 31, 2020 | 8.02 Mn |
| Dec 31, 2019 | 915,959.00 |
| Sep 30, 2019 | 7.53 Mn |
| Jun 30, 2019 | 946,071.00 |